RxDoctor Payments Data

Cyrus Badii, MD

Gastroenterology · West Hills, CANPI 1134274350

Payments from drug & device makers

$7,069in general payments, 2019–2025

Across 414 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$754
  • Johnson & Johnson$683
  • Pfizer$558
  • Ironwood Pharmaceuticals, Inc$535
  • Phathom Pharmaceuticals, Inc.$433
  • plus $2K from 18 others

What the payments were for

  • Food & beverage$7,069100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,069 in reported general payments places this provider in the 70th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$378,106
Medicare patients
786
Services billed
3,126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide76$58,215
Mesalamine19$8,900
Sucralfate20$4,731
Omeprazole356$3,459
Dexlansoprazole DrDexlansoprazole21$3,030
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates46$3,005
Esomeprazole Magnesium18$2,225
Chlordiazepoxide-ClidiniumChlordiazepoxide/Clidinium Br23$2,083
Famotidine149$1,315
Pantoprazole Sodium123$1,273
Hydrocortisone32$666
Ondansetron OdtOndansetron17$579
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl22$232
Lansoprazole14$184
LoperamideLoperamide Hcl11$137

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,826$58,21576 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in West Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →